Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Bethany Coomes, Christopher B. Hurt et al.|The Lancet HIV|2024Cited by 12
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01Yunda Huang, Maria P. Lemos, Heather Angier et al.|Nature Communications|2023Cited by 8
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01Deborah Donnell, Edith Swann, Lawrence Corey et al.|UNC Libraries|2025Cited by 0